<?xml version='1.0' encoding='utf-8'?>
<document id="19251820"><sentence text="Functional characterization of the human organic cation transporter 2 variant p.270Ala&gt;Ser." /><sentence text="The organic cation transporter 2 (OCT2, SLC22A2) plays an important role for renal drug elimination" /><sentence text=" Recent clinical studies indicate an impact of the frequent nonsynonymous c" /><sentence text="808G&gt;T (p" /><sentence text="270Ala&gt;Ser) polymorphism on renal clearance of metformin and the extent of the metformin-cimetidine interaction"><entity charOffset="47-56" id="DDI-PubMed.19251820.s5.e0" text="metformin" /><entity charOffset="79-88" id="DDI-PubMed.19251820.s5.e1" text="metformin" /><entity charOffset="89-99" id="DDI-PubMed.19251820.s5.e2" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.19251820.s5.e0" e2="DDI-PubMed.19251820.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19251820.s5.e0" e2="DDI-PubMed.19251820.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19251820.s5.e0" e2="DDI-PubMed.19251820.s5.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s5.e1" e2="DDI-PubMed.19251820.s5.e1" /><pair ddi="false" e1="DDI-PubMed.19251820.s5.e1" e2="DDI-PubMed.19251820.s5.e2" /></sentence><sentence text=" The role of this polymorphism for renal disposition of endogenous compounds and drugs other than metformin has not been investigated"><entity charOffset="98-107" id="DDI-PubMed.19251820.s6.e0" text="metformin" /></sentence><sentence text=" In addition, it is unclear whether the observed genotype dependence of an OCT2-mediated drug-drug interaction might occur also with other OCT inhibitors" /><sentence text=" To address these issues, we generated human embryonic kidney cells stably expressing wild-type OCT2 or the p" /><sentence text="270Ala&gt;Ser variant" /><sentence text=" No differences in protein expression levels and membrane incorporation pattern were observed between the two cell lines" /><sentence text=" The p" /><sentence text="270Ala&gt;Ser variant significantly impaired uptake kinetics of 1-methyl-4-phenylpyridinium, dopamine, norepinephrine, and propranolol"><entity charOffset="61-88" id="DDI-PubMed.19251820.s12.e0" text="1-methyl-4-phenylpyridinium" /><entity charOffset="90-98" id="DDI-PubMed.19251820.s12.e1" text="dopamine" /><entity charOffset="100-114" id="DDI-PubMed.19251820.s12.e2" text="norepinephrine" /><entity charOffset="120-131" id="DDI-PubMed.19251820.s12.e3" text="propranolol" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e0" e2="DDI-PubMed.19251820.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e0" e2="DDI-PubMed.19251820.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e0" e2="DDI-PubMed.19251820.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e0" e2="DDI-PubMed.19251820.s12.e3" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e1" e2="DDI-PubMed.19251820.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e1" e2="DDI-PubMed.19251820.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e1" e2="DDI-PubMed.19251820.s12.e3" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e2" e2="DDI-PubMed.19251820.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s12.e2" e2="DDI-PubMed.19251820.s12.e3" /></sentence><sentence text=" V(max) values were significantly reduced for uptake of all four compounds mediated by the p" /><sentence text="270Ala&gt;Ser variant compared with wild-type OCT2" /><sentence text=" In addition, a significant difference in the affinity to wild-type and mutant OCT2 was observed for dopamine (K(m) dopamine: 932 +/- 77 versus 1285 +/- 132 microM)"><entity charOffset="101-109" id="DDI-PubMed.19251820.s15.e0" text="dopamine" /><entity charOffset="116-124" id="DDI-PubMed.19251820.s15.e1" text="dopamine" /><pair ddi="false" e1="DDI-PubMed.19251820.s15.e0" e2="DDI-PubMed.19251820.s15.e0" /><pair ddi="false" e1="DDI-PubMed.19251820.s15.e0" e2="DDI-PubMed.19251820.s15.e1" /></sentence><sentence text=" Moreover, out of a set of 27 compounds p" /><sentence text="270Ala&gt;Ser OCT2 was significantly less sensitive to inhibition by cimetidine, flurazepam, metformin, mexiletine, propranolol, and verapamil than wild-type OCT2 (e"><entity charOffset="66-76" id="DDI-PubMed.19251820.s17.e0" text="cimetidine" /><entity charOffset="78-88" id="DDI-PubMed.19251820.s17.e1" text="flurazepam" /><entity charOffset="90-99" id="DDI-PubMed.19251820.s17.e2" text="metformin" /><entity charOffset="101-111" id="DDI-PubMed.19251820.s17.e3" text="mexiletine" /><entity charOffset="113-124" id="DDI-PubMed.19251820.s17.e4" text="propranolol" /><entity charOffset="130-139" id="DDI-PubMed.19251820.s17.e5" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e0" e2="DDI-PubMed.19251820.s17.e0" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e0" e2="DDI-PubMed.19251820.s17.e1" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e0" e2="DDI-PubMed.19251820.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e0" e2="DDI-PubMed.19251820.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e0" e2="DDI-PubMed.19251820.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e0" e2="DDI-PubMed.19251820.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e1" e2="DDI-PubMed.19251820.s17.e1" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e1" e2="DDI-PubMed.19251820.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e1" e2="DDI-PubMed.19251820.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e1" e2="DDI-PubMed.19251820.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e1" e2="DDI-PubMed.19251820.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e2" e2="DDI-PubMed.19251820.s17.e2" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e2" e2="DDI-PubMed.19251820.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e2" e2="DDI-PubMed.19251820.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e2" e2="DDI-PubMed.19251820.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e3" e2="DDI-PubMed.19251820.s17.e3" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e3" e2="DDI-PubMed.19251820.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e3" e2="DDI-PubMed.19251820.s17.e5" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e4" e2="DDI-PubMed.19251820.s17.e4" /><pair ddi="false" e1="DDI-PubMed.19251820.s17.e4" e2="DDI-PubMed.19251820.s17.e5" /></sentence><sentence text="g" /><sentence text=", for propranolol: IC(50) wild type versus p"><entity charOffset="6-17" id="DDI-PubMed.19251820.s19.e0" text="propranolol" /></sentence><sentence text="270Ala&gt;Ser 189 versus 895 microM, P &lt; 0" /><sentence text="001)" /><sentence text=" Our results indicate that the common OCT2 c" /><sentence text="808G&gt;T single nucleotide polymorphism significantly alters uptake of endogenous compounds and drugs" /><sentence text=" Moreover, for selected compounds the extent of OCT2-mediated drug interactions could depend on OCT2 c" /><sentence text="808G&gt;T genotype" /><sentence text="" /></document>